Sanofi and Regeneron received EU approval for broader use of Dupixent in treating chronic obstructive pulmonary disease (COPD), a significant step achieved faster than in the U.S. The EU Commission approved Dupixent for COPD patients not responsive to standard treatments, marking its expanded use beyond conditions like asthma and eczema.
